Bank of America initiated coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS - Free Report) in a research note published on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $30.00 target price on the stock.
Several other equities analysts have also recently weighed in on the company. Stifel Nicolaus started coverage on Kestra Medical Technologies in a research note on Monday. They set a "buy" rating and a $28.00 target price on the stock. Piper Sandler started coverage on shares of Kestra Medical Technologies in a research report on Monday. They set an "overweight" rating and a $27.00 price objective on the stock. Wells Fargo & Company began coverage on shares of Kestra Medical Technologies in a research report on Monday. They issued an "overweight" rating and a $28.00 target price for the company. The Goldman Sachs Group initiated coverage on shares of Kestra Medical Technologies in a report on Monday. They set a "neutral" rating and a $24.00 price target on the stock. Finally, Wolfe Research began coverage on Kestra Medical Technologies in a report on Monday. They set an "outperform" rating and a $29.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of "Moderate Buy" and an average target price of $27.67.
Read Our Latest Report on KMTS
Kestra Medical Technologies Stock Down 6.5 %
Shares of Kestra Medical Technologies stock traded down $1.68 during midday trading on Monday, hitting $24.02. The company's stock had a trading volume of 217,488 shares, compared to its average volume of 285,081. Kestra Medical Technologies has a 1-year low of $20.00 and a 1-year high of $26.06.
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Recommended Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
